Studying the Effects of Acetadote on Metabolism in Treating Patients with Newly Diagnosed Glioblastoma

Inclusion Criteria

• Glioblastoma
• Newly diagnosed with no prior surgery, radiation, chemotherapy, or other tumor-treating agent
• Age ≥ 18 years
• Karnofsky performance status (KPS) > 70
• Bilirubin ≤ 1.5 times upper limit of normal
• Aspartate aminotransferase (AST) ≤ 3 times upper limit of normal (ULN)
• Alanine aminotransferase (ALT) ≤ 3 times ULN
• Creatinine ≤ 1.5 x ULN and/or glomerular filtration rate (GFR) ≤ 60 mL/min
• Absolute neutrophil count (ANC) ≥ 1000 cells/ul
• Platelet ≥ 100,000/ul
• Hemoglobin ≥ 9 g/dl
• All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: ** Has not undergone a hysterectomy or bilateral oophorectomy; or ** Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
• Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria

• Chemotherapy, radiotherapy, or other cancer therapy within 4 weeks prior to starting study treatment
• Subjects must have recovered from prior treatment-related toxicities to grade 2 or baseline (excluding alopecia and clinically stable toxicities requiring ongoing medical management, such as hypothyroidism from prior immune checkpoint inhibitor treatment)
• Subjects may not be receiving any other investigational agents for the treatment of the cancer under study
• Brain metastases
• History of allergic or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to Acetadote
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements
• Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants